Generation Bio Co

GBIO

Company Profile

  • Business description

    Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

  • Contact

    301 Binney Street
    CambridgeMA02142
    USA

    T: +1 617 655-7500

    https://www.generationbio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    115

Stocks News & Analysis

stocks

Weekly earnings wrap: Last week’s winners & losers

A mixed first week for company’s reporting on the ASX. Here’s everything you need to know
stocks

Alphabet earnings: Continued momentum on cloud and search as capital expenses set to mount

Strong fourth quarter earnings.
stocks

Eli Lilly earnings: Revenue increases reflect global demand for oral obesity therapies

We’ve raised our fair value estimate of Lilly stock.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,954.60104.20-1.15%
CAC 408,273.8411.680.14%
DAX 4024,721.46230.400.94%
Dow JONES (US)50,115.671,206.952.47%
FTSE 10010,369.7560.530.59%
HKSE26,559.95325.29-1.21%
NASDAQ23,031.21490.632.18%
Nikkei 22554,253.68435.640.81%
NZX 50 Index13,388.5855.44-0.41%
S&P 5006,932.30133.901.97%
S&P/ASX 2008,708.8096.70-1.10%
SSE Composite Index4,065.5810.33-0.25%

Market Movers